Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 8/20 | 0.54 |
| ▸ | HRH1 | P35367 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245831 | 0.95 | HRH3 (0.61) | HRH3MAOBNPC1RAB9ABCHE | |
| SCHEMBL6848040 | 0.94 | HRH3 (0.58) | HRH3MAOBNPC1RAB9ABCHE | |
| SCHEMBL1335721 | 0.85 | HRH3 (0.62) | HRH3MAOBNPC1RAB9ABCHE | |
| SCHEMBL17949768 | 0.85 | HRH3 (0.61) | HRH3MAOBNPC1RAB9ABCHE | |
| SCHEMBL17941713 | 0.85 | HRH3 (0.61) | HRH3MAOBNPC1RAB9ABCHE | |
| SCHEMBL30949365 | 0.83 | HRH3 (0.59) | HRH3MAOBNPC1RAB9ABCHE | |
| SCHEMBL20021242 | 0.81 | HPGD (0.63) | HRH3MAOBNPC1RAB9ABCHE | |
| SCHEMBL9156027 | 0.79 | NPC1 (0.60) | HRH3MAOBNPC1RAB9AHRH2 | |
| SCHEMBL17949867 | 0.78 | HRH2 (0.56) | HRH3MAOBNPC1RAB9ABCHE | |
| SCHEMBL12516203 | 0.78 | GAA (0.59) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301480-B1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1467727-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| WO-2003059341-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| US-6559140-B2 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBVIE INC. | 2001-12-06 | — | — | US | disclosed |
| WO-2001066534-A2 | CYCLIC AND BICYCLIC DIAMINO HISTAMINE-3 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | HRH4, HRH2, HRH3 | HRH3 3/4885MAOB 251/4885NPC1 3335/4885 |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885MAOB 1114/4885NPC1 2137/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885MAOB 1114/4885NPC1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.